대한두경부종양학회지 (Korean Journal of Head & Neck Oncology)

  • 제24권1호
  • /
  • Pages.64-68
  • /
  • 2008
  • /
  • 1229-5183(pISSN)
  • /
  • 2586-2553(eISSN)
대한두경부종양학회 (The Korean Society for Head and Neck Oncology)
권호 표지

신장이식후 발생한 유두상 갑상선암

Papillary Thyroid Carcinoma in Renal Allograft Recipients

  • 이잔디 (아주대학교 의과대학 외과학교실) ;
  • 홍협 (아주대학교 의과대학 외과학교실) ;
  • 정종주 (연세대학교 의과대학 외과학교실) ;
  • 남기현 (연세대학교 의과대학 외과학교실) ;
  • 정웅윤 (연세대학교 의과대학 외과학교실) ;
  • 소의영 (아주대학교 의과대학 외과학교실) ;
  • 박정수 (연세대학교 의과대학 외과학교실)
  • Lee, Jan-Dee (Department of Surgery, Ajou University College of Medicine) ;
  • Hong, Hyeop (Department of Surgery, Ajou University College of Medicine) ;
  • Jeong, Jong-Ju (Department of Surgery, Yonsei University College of Medicine) ;
  • Nam, Kee-Hyun (Department of Surgery, Yonsei University College of Medicine) ;
  • Chung, Woong-Youn (Department of Surgery, Yonsei University College of Medicine) ;
  • Soh, Euy-Young (Department of Surgery, Ajou University College of Medicine) ;
  • Park, Cheong-Soo (Department of Surgery, Yonsei University College of Medicine)
  • 발행 : 2008.05.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Purpose：The chronic use of immunosuppressive therapy in transplant recipients can increase the long-term risk of carcinoma. The aim of this study was to determine the incidence, biological behaviors, and treatment outcomes in PTC(papillary thyroid carcinoma) in renal allograft recipients. Material and Methods：The present study examined the incidence and biological behavior of PTCs in RA recipients. A total of 1,739 RA patients treated between January 1986 and December 1999 were followed-up for a median 137(84-238) months. During the follow-up period, 129(7.4%) recipients were identified as having posttransplant malignancies. Of those, 12(0.7%) had PTCs, and these comprised six male and six female patients with a median age of 41(23-57) years. Results：Nine cases(incidentalomas) were diagnosed based on ultrasonography(US) screening. Eight of those nine were TNM stage I, and two of the three clinical carcinomas were TNM stage IVa. During a median follow-up of 94(18-159) months, two(16.7%) PTC patients developed loco-regional recurrence, but no patients showed distant metastasis. Posttransplant PTC showed no gender bias, and was often associated with aggressive lymphatic metastasis. However, most incidentalomas showed a favorable treatment outcome. Conclusion：In conclusion, routine surveillance of the thyroid gland using US screening is recommended to ensure early detection, treatment and favorable prognosis in RA patients with PTC.

키워드

참고문헌

  1. London NJ, Farmery SM, Will EJ, Davison AM, Lodge JP: Risk of neoplasia in renal transplant patients. Lancet. 1995;346:403-406 https://doi.org/10.1016/S0140-6736(95)92780-8
  2. Veroux M, Puliatti C, Fiamingo P, et al: Early de novo malignancies after kidney transplantation. Transplant Proc. 2004;36: 718-720 https://doi.org/10.1016/j.transproceed.2004.03.021
  3. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C: Cancer after kidney transplantation in the United States. Am J Transplant. 2004;4:905-913 https://doi.org/10.1111/j.1600-6143.2004.00450.x
  4. Brunner FP, Landais P, Selwood NH: Malignancies after renal transplantation: the EDTA-ERA registry experience. European Dialysis and Transplantation Association-European Renal Association. Nephrol Dial Transplant. 1995;10:74-80
  5. Fahey TJ 3rd, Reeve TS, Delbridge L: Increasing incidence and changing presentation of thyroid cancer over a 30-year period. Br J Surg. 1995;82:518-520 https://doi.org/10.1002/bjs.1800820426
  6. Franceschi S, La Vecchia C: Thyroid cancer. Cancer Surv. 1994; 19-20:393-422
  7. Nemes B, Zalatnai A, Podder H, et al: Papillary microcarcinoma of the thyroid gland in renal transplant patients. Pathol Oncol Res. 2000;6:72-75 https://doi.org/10.1007/BF03032662
  8. Korea Central Cancer Registry Working Group: Korea Cancer Statistics: 1996 Incidence. Seoul. GA: Department of Disease Control and Prevention Services. National Health Insurance Cooperation and Nation Cancer Institute, 2004.Korean cancer Survellence, 2007:1190
  9. Shah JP: AJCC Cancer Staging Handbook. TNM classification of malignant tumors, 6th ed. In: Greene FL(ed) Springer-Verlag, New York, 2002:77-78
  10. Keast D: Immunosurveillance and cancer. Lancet. 1970;2:710-712
  11. Schwartz RS: Immunoregulation, oncogenic viruses, and malignant lymphomas. Lancet. 1972;1:1266-1269
  12. Suzuki T, Takano Y, Yamashita K, Sato K, Kakita A, Okudaira M: A possible role for Epstein-Barr virus in tumorigenesis after immunosuppression in cases of renal transplantation. J Cancer Res Clin Oncol. 1993:119:627-629 https://doi.org/10.1007/BF01372727
  13. Penn I: Cancers following cyclosporine therapy. Transplantation. 1987;43:32-35 https://doi.org/10.1097/00007890-198701000-00008
  14. Penn I: Cancer is a complication of severe immunosuppression. Surg Gynecol Obstet. 1986;162:603-610
  15. First MR, Peddi VR: Malignancies complicating organ transplantation. Transplant Proc. 1998;30:2768-2770 https://doi.org/10.1016/S0041-1345(98)00805-7
  16. Nafar M, Einollahi B, Hemati K, Gholi FP, Firouzan A: Development of malignancy following living donor kidney transplantation. Transplant Proc. 2005;37:3065-3067 https://doi.org/10.1016/j.transproceed.2005.08.011
  17. Wang CX, Liu LS, Chen LZ, et al: Characteristics of neoplasm occurrence and the therapeutic effect of Sirolimus in South Chinese kidney transplant recipients. Transplant Proc. 2006;38:3536-3539 https://doi.org/10.1016/j.transproceed.2006.10.070
  18. Pond F, Serpell JW, Webster A: Thyroid cancer in the renal transplant population: epidemiological study. ANZ J Surg. 2005; 75:106-109 https://doi.org/10.1111/j.1445-2197.2005.03311.x
  19. Samhan M, Al-Mousawi M, Donia F, Fathi T, Nasim J, Nampoory MR: Malignancy in renal recipients. Transplant Proc. 2005;37:3068-3070 https://doi.org/10.1016/j.transproceed.2005.07.046
  20. Hoshida Y, Aozasa K: Malignancies in organ transplant recipients. Pathol Int. 2004;52:649-658